Long-acting amylin analog
Cagrilintide
An investigational amylin analog with human trial evidence but no general marketing authorization in Canada or the United States.
Why it is discussed
Obesity and metabolic research
Cagrilintide is discussed as a long-acting amylin analog being studied alone and with semaglutide for weight-management and metabolic outcomes. Controlled trials provide human evidence in defined study settings, but they do not authorize online products, establish self-directed use, or verify that a research vial contains the studied molecule.
What it is
A modified amylin analog—not a GLP-1 peptide.
Cagrilintide is a long-acting analog of amylin, a hormone released by pancreatic beta cells alongside insulin. Its molecular modifications, including an attached lipid group, were designed to support prolonged action. Although it is discussed alongside GLP-1 medicines, it belongs to a different hormone pathway.
How it works
Amylin-family receptor signaling involved in fullness.
Amylin signaling contributes to satiation, the process that helps bring a meal to an end. Cagrilintide activates amylin receptors and also the calcitonin receptor. Amylin receptors contain a calcitonin-receptor component combined with a receptor activity-modifying protein, or RAMP.
Structural experiments show how cagrilintide engages these receptor complexes. They explain target recognition, but do not determine how much each receptor contributes to a person's appetite or weight response. Human trials test clinical outcomes separately.
The receptor mechanism does not establish equivalence to natural amylin, prove the quality of a research vial, or validate combining it with another compound. Evidence for a studied combination must remain specific to that combination and preparation.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Investigational human clinical evidence
Controlled human trials support effects on weight-related and metabolic outcomes for cagrilintide in defined investigational settings.
Cagrilintide is not an authorized product in Canada or the United States, and trial findings do not verify online material, establish self-directed use, or transfer to products outside the studies.
Regulatory status
Canada and the United States are checked separately.
No Health Canada-authorized cagrilintide product was identified in the current Drug Product Database review. Canadian trial activity is research activity, not market authorization.
Not FDA approved. FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.